Curriculum Vitae

Personal Data

Title	Prof. Dr. med.
First name	Judith
Name	Alferink
Current position	W3 Professor
Current institution(s)/ site(s), country	Department of Psychiatry and Psychotherapy, Faculty of Medicine, UKM, Universität Münster (UMS), Germany Alexianer Münster GmbH, Germany
Identifiers/ORCID	0000-0002-3251-6584

Qualifications and Career

Stages	Periods and Details	
Degree programme	1982–1989	Medicine, Julius-Maximilians-Universität Würzburg, Germany
Doctorate	1994	Dissertation, Tumor Immunology, "Peripheral T cell tolerance in transgenic mice", Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Germany
Stages of academic/ professional career	2018–present	Professor of Immunobiology of Psychiatric Disorders (W3), UMS, Germany
	2017–present	Head of the Hospital of Psychiatry and Psychotherapy, Alexianer Münster GmbH, Germany
	2012–2017	Senior physician and group leader, Dept. of Psychiatry and Psychotherapy, UKM, Germany
	2013	Habilitation in Psychiatry and Psychotherapy, UMS, Germany
	2012	Board Certificate, Psychiatry, Germany
	2005–2012	Physician and group leader, Dept. of Psychiatry and Institute of Molecular Psychiatry, University of Bonn, Germany
	2004–2005	Physician, Department of Psychiatry, Mental Health Clinic, Ingolstadt, Germany
	2003–2004	Group leader, Institute for Molecular Medicine and Experimental Immunology, University of Bonn, Germany
	1998–2002	Residency and postdoctoral fellowship, Institute of Medical Microbiology, Immunology, and Hygiene, University München, Germany
	1994–1998	Postdoctoral fellowship, Institute of Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
	1989–1994	Doctoral thesis, Institute of Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany

Engagement in the Research System

since 2022 Member of the Scientific Advisory Board, Alzheimer Forschung Initiative (AFI)

since 2015 Member of the Steering Committee German-Endocrine-Brain-Immune-Network (GEBIN)

2013–2019 Member of the DFG-Excellence Cluster "Cells in Motion" (EXC 1003 – CiM, UMR)

Supervision of Researchers in Early Career Phases

- Provision of study courses, lectures, and seminars for undergraduate, graduate and postgraduate students in biology and (experimental) medicine on scientific topics such as (neuro)immunology, neurobiology, and psychiatry. Since 2018, personal supervision of 15 PhD and Master students.

Scientific Results

Contributions: [1]Conceptualization/Methodology, [2]Analysis, [3]Investigation, [4]Funding Acquisition, [5]Writing

Category A (10 selected publications out of 62)

Freff J, …, **Dannlowski U**, Nöthen MM, Baune BT, **Forstner AJ***, **Alferink J***[1,2,3,4,5]: Chemokine receptor 4 expression on blood T lymphocytes predicts severity of major depressive disorder. J Affect Disord 2022; 310:343-353. DOI: 10.1016/j.jad.2022.05.003

Freff J, …, **Dannlowski U**, …, Föcker M*, **Alferink J***[1,2,3,4,5]: Expression of CXCR4 on CD4(+) T cells predicts body composition parameters in female adolescents with anorexia nervosa. Front Psychiatry 2022; 13:960905. DOI: 10.3389/fpsyt.2022.960905

Freff J, …, **Dannlowski U**, …, Föcker M*, **Alferink J***[1,2,3,4,5]: Alterations in B cell subsets correlate with body composition parameters in female adolescents with anorexia nervosa. Sci Rep 2021; 11(1):1125. DOI: 10.1038/s41598-020-80693-4

Ahmetspahic D, …, **Dannlowski U**, Arolt V, Scheu S*, **Alferink J***[1,2,3,4,5]: Altered B cell homeostasis in patients with major depressive disorder and normalization of CD5 surface expression on regulatory B cells in treatment responders. J Neuroimmune Pharmacol 2018; 13(1):90-99. DOI: 10.1007/s11481-017-9763-4

Ambree O, …, **Alferink J**[1,2,3,4,5]: Alterations of the innate immune system in susceptibility and resilience after social defeat stress. Front Behav Neurosci 2018; 12:141. DOI: 10.3389/fnbeh.2018.00141

Ruland C, …, **Klotz L**, Förster I, Scheu S*, **Alferink J***[1,2,3,4,5]: Chemokine CCL17 is expressed by dendritic cells in the CNS during experimental autoimmune encephalomyelitis and promotes pathogenesis of disease. Brain Behav Immun 2017; 66:382-393. DOI: 10.1016/j.bbi.2017.06.010

Ambree O, …, **Alferink J**[1,2,3,4,5]: Reduced locomotor activity and exploratory behavior in CC chemokine receptor 4 deficient mice. Behav Brain Res 2016; 314:87-95. DOI: 10.1016/j.bbr.2016.07.041

Poppensieker K*, Otte DM*, Schürmann B*, …, **Klotz L**, …, Zimmer A*, **Alferink J***[1,2,3,4,5]: CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells. Proc Natl Acad Sci U S A 2012; 109(10):3897-3902. DOI: 10.1073/pnas.1114153109

Alferink J*[1,2,3,5], Lieberam I*, …, Förster I: Compartmentalized production of CCL17 in vivo: strong inducibility in peripheral dendritic cells contrasts selective absence from the spleen. J Exp Med 2003; 197(5):585-599. DOI: 10.1084/jem.20021859

Alferink J[1,2,3,5], …, Arnold B: Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 1998; 282(5392):1338-1341. DOI: 10.1126/science.282.5392.1338

Category B

Kircher T, **Wöhr M**, **Nenadić I**, …, **Alferink J**[1,2,3,4,5], **Culmsee C**, Garn H, **Hahn T**, …, **Jansen A**, …, **Dannlowski U**: Neurobiology of the major psychoses: A translational perspective on brain structure and function – the FOR 2107 consortium. Eur Arch Psychiatry Clin Neurosci 2019; 269(8):949-962. DOI: 10.1007/s00406-018-0943-x

Science communication

n/a

Academic Distinctions

2014 Research Award Alzheimer Forschung Initiative e.V., Germany

Other Information

n/a